Image from Google Jackets

Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations.

By: Contributor(s): Publication details: 2010ISSN:
  • 14642662
Uniform titles:
  • HIV Medicine
Online resources: Summary: <span style="font-size: 8pt;"><br /></span><div style="line-height: 17.999801635742188px;"><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">OBJECTIVE:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">Effective&nbsp;<span class="highlight">antiretroviral</span>&nbsp;therapy (ART) has transformed the care of people with&nbsp;<span class="highlight">HIV</span>, but it is important to monitor&nbsp;<span class="highlight">time</span>&nbsp;<span class="highlight">trends</span>&nbsp;in indicators of&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">success</span>&nbsp;and antic future changes.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">METHODS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">We assessed&nbsp;<span class="highlight">time</span>&nbsp;<span class="highlight">trends</span>&nbsp;from 2000 to 2007 in several indicators of&nbsp;<span class="highlight">treatment</span>&nbsp;<span class="highlight">success</span>&nbsp;in the UK Collaborative&nbsp;<span class="highlight">HIV</span>&nbsp;Cohort (CHIC) Study, and using national&nbsp;<span class="highlight">HIV</span>&nbsp;data from the Health Protection Agency (HPA) we developed a model to project future&nbsp;<span class="highlight">trends</span>.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">The proportion of patients on ART with a viral load <50&nbsp;<span class="highlight">HIV</span>-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count <200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class&nbsp;<span class="highlight">failure</span>&nbsp;(ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load >50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of&nbsp;<span class="highlight">success</span>, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads >50 copies/mL. Numbers of deaths are projected to remain low.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">CONCLUSIONS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">There have been continued improvements in key indicators of&nbsp;<span class="highlight">success</span>&nbsp;in patients with&nbsp;<span class="highlight">HIV</span>&nbsp;from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads >50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive&nbsp;<span class="highlight">trends</span>.</span></p></div>
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Collection Class number Status Date due Barcode
Book Ferriman information and Library Service (North Middlesex) Shelves Staff publications for NMDX Available

NMUH Staff Publications

11

&lt;span style="font-size: 8pt;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;div style="line-height: 17.999801635742188px;"&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;OBJECTIVE:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;Effective&amp;nbsp;&lt;span class="highlight"&gt;antiretroviral&lt;/span&gt;&amp;nbsp;therapy (ART) has transformed the care of people with&amp;nbsp;&lt;span class="highlight"&gt;HIV&lt;/span&gt;, but it is important to monitor&amp;nbsp;&lt;span class="highlight"&gt;time&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;trends&lt;/span&gt;&amp;nbsp;in indicators of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;success&lt;/span&gt;&amp;nbsp;and antic future changes.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;We assessed&amp;nbsp;&lt;span class="highlight"&gt;time&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;trends&lt;/span&gt;&amp;nbsp;from 2000 to 2007 in several indicators of&amp;nbsp;&lt;span class="highlight"&gt;treatment&lt;/span&gt;&amp;nbsp;&lt;span class="highlight"&gt;success&lt;/span&gt;&amp;nbsp;in the UK Collaborative&amp;nbsp;&lt;span class="highlight"&gt;HIV&lt;/span&gt;&amp;nbsp;Cohort (CHIC) Study, and using national&amp;nbsp;&lt;span class="highlight"&gt;HIV&lt;/span&gt;&amp;nbsp;data from the Health Protection Agency (HPA) we developed a model to project future&amp;nbsp;&lt;span class="highlight"&gt;trends&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;The proportion of patients on ART with a viral load &amp;lt;50&amp;nbsp;&lt;span class="highlight"&gt;HIV&lt;/span&gt;-1 RNA copies/mL increased from 62% in 2000 to 84% in 2007, and the proportion of all patients with a CD4 count &amp;lt;200 cells/microL decreased from 21% to 10%. During this period, the number of patients who experienced extensive triple class&amp;nbsp;&lt;span class="highlight"&gt;failure&lt;/span&gt;&amp;nbsp;(ETCF) rose from 147 (0.9%) to 1771 (3.9%). The number who experienced such ETCF and had a current viral load &amp;gt;50 copies/mL rose fromz 118 (0.7%) to 857 (1.9%). Projections to 2012 suggest sustained high levels of&amp;nbsp;&lt;span class="highlight"&gt;success&lt;/span&gt;, with a continued increase in the number of patients who have failed multiple drugs but a relatively stable number of such patients experiencing viral loads &amp;gt;50 copies/mL. Numbers of deaths are projected to remain low.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;CONCLUSIONS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;There have been continued improvements in key indicators of&amp;nbsp;&lt;span class="highlight"&gt;success&lt;/span&gt;&amp;nbsp;in patients with&amp;nbsp;&lt;span class="highlight"&gt;HIV&lt;/span&gt;&amp;nbsp;from 2000 to 2007. Although the number of patients who have ETCF is projected to rise in the future, the number of such patients with viral loads &amp;gt;50 copies/mL is not projected to increase up to 2012. New drugs may be needed in future to sustain these positive&amp;nbsp;&lt;span class="highlight"&gt;trends&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;

There are no comments on this title.

to post a comment.
London Health Libraries Koha Consortium privacy notice